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http://dx.doi.org/10.1016/j.ccell.2015.02.016SUMMARYChromosomal translocations affectingmixed lineage leukemia gene (MLL) result in acute leukemias resistant
to therapy. The leukemogenic activity of MLL fusion proteins is dependent on their interaction with menin,
providing basis for therapeutic intervention. Here we report the development of highly potent and orally
bioavailable small-molecule inhibitors of the menin-MLL interaction, MI-463 and MI-503, and show their pro-
found effects inMLL leukemia cells and substantial survival benefit inmousemodels ofMLL leukemia. Finally,
we demonstrate the efficacy of these compounds in primary samples derived from MLL leukemia patients.
Overall, we demonstrate that pharmacologic inhibition of the menin-MLL interaction represents an effective
treatment for MLL leukemias in vivo and provide advanced molecular scaffold for clinical lead identification.INTRODUCTION
Acute leukemias represent a paradigm for understanding how
genetic and epigenetic modifications lead to tumorigenesis (Fig-Significance
Chromosomal translocations of MLL occur in aggressive acu
proteins requiremenin for leukemogenic activity, and selective
therapeutic approach for acute leukemias with MLL rearrange
orally bioavailable small-molecule inhibitors of the menin-MLL
progression of MLL leukemia in vitro and in vivo, without affec
these compounds in primary leukemia samples derived from M
clinical evaluation of the menin-MLL inhibitors as a valuable the
rearrangements.ueroa et al., 2010; Rodrı´guez-Paredes and Esteller, 2011).
Despite the complexity of these alterations, which represent a
challenge in developing targeted therapies, numerous efforts
have been focused on developing effective agents for acutete leukemias affecting both children and adults. MLL fusion
targeting of themenin-MLL interaction represents a potential
ments. Here, we report the development of very potent and
interaction, MI-463 and MI-503, which effectively block the
ting normal hematopoiesis. We also demonstrate efficacy of
LL leukemia patients. These studies provide a rationale for
rapeutic approach for acute leukemias associated withMLL
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leukemias (Daigle et al., 2011; Dawson et al., 2011; Peloquin
et al., 2013; Zuber et al., 2011). Acute leukemias with transloca-
tions of the mixed lineage leukemia gene (MLL), which constitute
about 5% to 10% of acute leukemias in adults (Marschalek,
2011) and 70% of acute leukemias in infants (Tomizawa
et al., 2007), still represent mostly incurable diseases (Dimartino
and Cleary, 1999; Marschalek, 2011). Fusion of MLL with 1 of
more than 60 partner genes leads to expression of chimeric
MLL fusion proteins, all of which retain an approximately 1,400
amino acid N-terminal fragment of MLL fused with the fusion
partner (Hess, 2004; Krivtsov and Armstrong, 2007; Slany,
2009). Expression of MLL fusion proteins enhances proliferation
and blocks differentiation of hematopoietic cells, ultimately lead-
ing to acute leukemia (Slany, 2005). Patients with MLL leukemias
respond poorly to currently available treatments (Slany, 2005),
with a 5-year overall survival rate of only about 35% (Dimartino
and Cleary, 1999), emphasizing the urgent need for development
of more effective therapies.
The MLL fusion proteins interact with menin, a protein that
binds to the N-terminal fragment of MLL retained in all MLL
fusion proteins (Caslini et al., 2007; Grembecka et al., 2010; Yo-
koyama and Cleary, 2008; Yokoyama et al., 2005). Numerous
studies demonstrated a critical role of menin as an oncogenic
cofactor in leukemic transformations mediated by MLL fusion
proteins (Caslini et al., 2007; Yokoyama and Cleary, 2008; Yo-
koyama et al., 2005). Menin is a highly specific and direct binding
partner of MLL and MLL fusion proteins that is required for regu-
lation of their target genes (Yokoyama et al., 2005). Genetic
disruption of themenin-MLL fusion protein interaction abrogates
oncogenic properties of MLL fusion proteins and blocks the
development of acute leukemia in vivo (Yokoyama et al., 2005).
These data, together with the evidence that menin is not a requi-
site cofactor of MLL1 during normal hematopoiesis (Li et al.,
2013), validate the menin-MLL interaction as an attractive thera-
peutic target to develop targeted drugs for MLL leukemia
patients.
Despite the critical role of menin in leukemogenesis mediated
by MLL fusion proteins, it remains unknown whether pharmaco-
logical inhibition of the menin-MLL interaction can suppress
development of acute leukemia in vivo and whether it would
affect normal hematopoiesis. We previously reported first-gen-
eration small-molecule inhibitors of the menin-MLL interaction
(Grembecka et al., 2012; He et al., 2014; Shi et al., 2012), which
represent valuable tool compounds but are not suitable for in vivo
studies because of moderate cellular activity and poor pharma-
cological properties. The goal of this study was to develop highly
potent small-molecule inhibitors of the menin-MLL interaction
with appropriate pharmacokinetic (PK) profile and to determine
whether small-molecule inhibition of the menin-MLL interaction
can represent a valid therapeutic approach for acute leukemias
associated with MLL rearrangements.
RESULTS
Structure-Based Development of Potent Menin-MLL
Inhibitors
To develop menin-MLL inhibitors with favorable druglike proper-
ties suitable for in vivo efficacy studies, we used structure-based
design and very substantially reengineered our previously re-590 Cancer Cell 27, 589–602, April 13, 2015 ª2015 Elsevier Inc.ported compounds represented by the most potent MI-2-2 (Fig-
ure S1A) (Grembecka et al., 2012; Shi et al., 2012). Although
MI-2-2 represents a useful chemical tool, it is not suitable for
in vivo efficacy studies, because of modest cellular activity and
very poor metabolic stability (Figures S1A–S1C). Using the crys-
tal structure of the menin-MI-2-2 complex (Shi et al., 2012) we
used structure-based design combined with medicinal chemis-
try efforts, resulting in the development of menin-MLL inhibitors
with modified molecular scaffold (Table S1). These efforts led to
the identification of MI-136 (Figure 1A), which was developed by
introducing the cyano-indole ring connected to the thienopyrimi-
dine core via a piperidine linker (Table S1). MI-136 demonstrates
potent inhibitory activity and strong binding affinity tomenin (Fig-
ure 1A), providing an excellent molecular scaffold for further
modifications. On the basis of the binding mode of MI-136 to
menin (Figure S1D), we explored three substitution sites on the
indole ring of MI-136 (R1, R2, and R3; Figure 1B) to further
improve potency and druglike properties by optimizing hydro-
phobic contacts (at R2) or polar interactions (at R1 andR3) (Table
S2). The molecular determinants for recognition of MI-136 ana-
logs in the MLL binding site on menin are summarized in Fig-
ure 1B. Our medicinal chemistry efforts resulted in identification
of two lead compounds, MI-463 and MI-503, which were ob-
tained by combining two (MI-463) or three (MI-503) best substit-
uents on the indole ring (Figure 1C; Table S2).MI-503 andMI-463
are the most potent inhibitors we developed, both bind to menin
with low-nanomolar binding affinities, and demonstrate very
potent inhibition of the menin-MLL interaction (Figures 1C, 1D,
and S1E). Crystal structure validates binding of MI-503 to the
MLL site on menin (Figure 1E; Table S3). MI-503 occupies the
F9 and P13 pockets on menin, forming a hydrogen bond with
Tyr276, and also extends beyond the P13 pocket to form
hydrogen bonds with Trp341 and Glu366 (Figure 1E). In addition
to strong in vitro potency, MI-463 and MI-503 have very
favorable druglike properties, including metabolic stability (Fig-
ure S1C) and PK profile in mice (see below), which makes
them very attractive candidates to evaluate the therapeutic
potential of menin-MLL inhibitors in vivo.
MI-503 and MI-463 Demonstrate Selective and
On-Target Activity in MLL Leukemia Cells
We performed a detailed characterization of MI-463 and MI-503
in MLL leukemia cells to assess their activity, selectivity and vali-
date the mechanism of action. First, we found that both com-
pounds can reach the target protein in mammalian cells and
effectively inhibit the menin-MLL-AF9 interaction at sub-micro-
molar concentrations, as assessed in the co-immunoprecipita-
tion experiment (Figure 2A). Treatment of murine bone marrow
cells (BMC) transformed with the MLL-AF9 oncogene with
MI-463 and MI-503 resulted in substantial growth inhibition,
with half-maximal growth inhibitory concentration (GI50) values
of 0.23 mM and 0.22 mM, respectively, measured after 7 days
of treatment (Figure 2B). The cell growth inhibitory effect of MI-
503 was time dependent, with a pronounced effect achieved
after 7 to 10 days of treatment (Figure S2A), which is similar to
other small molecule inhibitors of epigenetic targets, including
DOT1L (Bernt et al., 2011) and EZH2 (Knutson et al., 2012). MI-
463 and MI-503 were selective toward MLL-AF9 BMCs, as no
cell growth inhibition was observed in BMCs transformed with
Figure 1. Structure-Based Development of
Potent Menin-MLL Inhibitors
(A) Chemical structure and in vitro activity for
MI-136. IC50 was measured by fluorescence po-
larization assay, and Kd was determined by ITC.
(B) Summary of structure-activity relationship for
menin-MLL inhibitors. R1, R2, and R3 indicate
substitution sites explored for modifications. Best
substituents at R1, R2, and R3 positions are
shown.
(C) Structures and activities of MI-463 and MI-503
menin-MLL inhibitors.
(D) Binding isotherm from ITC for MI-503 binding
to menin, demonstrating binding affinity (Kd) and
stoichiometry (N).
(E) Crystal structure of MI-503 bound to menin.
Protein is shown in ribbon representation, and key
menin residues involved in interactions with MI-
503 are shown as sticks. MI-503 is shown in stick
representation with colors corresponding to the
atom type (green, carbons; dark blue, nitrogens;
yellow, sulfur; light blue, fluorine). Dashed lines
represent hydrogen bonds between the ligand and
protein.
See also Figure S1 and Tables S1–S3.the Hoxa9/Meis1 oncogenes (HM-2; Figure 2B). Similarly, we
observed pronounced growth suppressive activity of MI-503
and MI-463 in a panel of human MLL leukemia cell lines (GI50
in the 250–570 nM range for MI-503) but only a minimal effect
in human leukemia cell lines withoutMLL translocations (Figures
2C and S2B). Selective killing of MLL leukemia cells is attributed
to inhibition of the menin-MLL interaction as the close analogs
MI-372 and MI-405, which are much weaker menin-MLL inhibi-
tors (half-maximal inhibitory concentration [IC50] = 0.92 and
15.6 mM, respectively), did not show growth suppressive effects
in MLL leukemia cells (Figures S2C–S2F).
MI-503 and MI-463 were also very effective in inducing differ-
entiation of MLL leukemia cells, as reflected by pronounced
phenotypic changes from primitive blasts to more mature
myeloid cells, and substantially increased expression of
CD11b, a myeloid differentiation marker (Figures 2D–2F and
S2G–S2I). These effects were accompanied by reduced c-kit
(CD117) expression, a marker associated with leukemia stemCancer Cell 27, 589–6cells (LSCs) (Krivtsov et al., 2006; Somer-
vaille and Cleary, 2006) (Figures S2J and
S2K). Interestingly, effects on apoptosis
were less pronounced, as higher con-
centrations of both compounds were
required for pronounced apoptotic effect
in MLL leukemia cells (Figure 2G). Treat-
ment with sub-micromolar concentra-
tions of MI-503 and MI-463 also led to
markedly reduced expression of Hoxa9
and Meis1, downstream targets of MLL
fusion proteins substantially upregulated
in MLL leukemias (Figure 2H). Overall,
we developed very potent menin-MLL
inhibitors, which selectively block prolif-
eration of MLL leukemia cells througha specific, on-target mechanism of action, representing very
promising candidates for in vivo studies.
To assess the effect of a long-term treatment combined with
compound withdrawal we treated MV4;11 human leukemia cells
expressing MLL-AF4 with MI-503 followed by the wash-out
phase to eliminate the compound and subsequent resupply
with MI-503, with each phase continuing for 10 days (Figures
2I and S2L). To avoid cell death, MI-503 was used at 0.2 to
0.6 mM concentrations that inhibit proliferation but do not induce
high-level apoptosis. As expected, MI-503 inducedmarked anti-
proliferative effects in the first treatment phase, with a GI50 value
of 200 nM at day 10 (Figure 2I). Withdrawal of MI-503 restored
proliferation ofMV4;11 cells; however, this effect was concentra-
tion dependent, and less pronounced recovery was observed for
cells treated with the highest MI-503 concentration (Figure 2I).
Restoration of MI-503 treatment at day 21 resulted in further in-
hibition of MV4;11 cell proliferation (Figures 2I and S2L). Interest-
ingly, upon prolonged treatment with 0.6 mM of MI-503, the02, April 13, 2015 ª2015 Elsevier Inc. 591
Figure 2. Activity of Menin-MLL Inhibitors in MLL Leukemia Cells
(A) Co-immunoprecipitation experiment in human embryonic kidney 293 (HEK293) cells transfected with MLL-AF9 upon treatment with DMSO, MI-463, and
MI-503. Control (cntrl) represents an untransfected sample.
(legend continued on next page)
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MV4;11 cells began exhausting their proliferative potential (Fig-
ure S2L, bottom). Furthermore, expression of HOXA9 and
MEIS1 was markedly reduced at the end of each treatment
phase (days 10 and 30) (Figure 2J). In contrast, expression of
HOXA9 and MEIS1 was restored to the DMSO control level at
the end of the wash-out phase (day 20) (Figure 2J). These data
support the need for continuous inhibition of menin to block
the activity of MLL fusion oncogenes. The ability to suppress
proliferation of MV4;11 cells using prolonged treatment with
MI-503 suggests that resistance did not develop over the dura-
tion of the experiment.
Menin-MLL Inhibitors Reverse Gene Expression
Signatures Associated with MLL-Rearranged
Leukemia Cells
To assess the effects of menin-MLL inhibitors on global gene
expression in the MLL-rearranged leukemias, we performed
gene expression studies in MV4;11 human leukemia cells (ex-
pressing MLL-AF4) after treatment with the MI-389 menin-MLL
inhibitor, a close analog of MI-503 with a similar in vitro and
cellular activity (Figures S3A and S3B). Significant changes in
gene expression were found for 478 and 477 genes up- and
downregulated, respectively (Table S4). Gene set enrichment
analysis (GSEA) demonstrated strong downregulation of genes
identified as downstream targets of MLL-AF4 (Guenther et al.,
2008) and MLL-AF9 (Bernt et al., 2011) following treatment
with MI-389 (Figures 3A and 3B). These included multiple genes
implicated in MLL fusion protein mediated leukemogenesis,
such as homeobox genes (HOXA9, HOXA10, MEIS1, and
PBX3), FLT3, and other downstream targets of MLL fusion
proteins (MEF2C, BCL2, and CDK6) (Figures 3A and 3B; Table
S4). Downregulated expression of these genes was consistent
with phenotypic consequences of treatment with the menin-
MLL inhibitor (Figure S3C). GSEA also revealed a global
upregulation of genes underexpressed in LSCs (CD34+ CD38
progenitor cells) (Gal et al., 2006) and in primitive hematopoietic
progenitor cells (Jaatinen et al., 2006), including genes associ-
ated with differentiation (ITGAM, which encodes the cell sur-
face marker CD11b associated with myeloid differentiation,
and MNDA), following MI-389 treatment (Figure 3C).
We have further used quantitative RT-PCR (qRT-PCR) to vali-
date expression changes for selected genes in MV4;11 and
MOLM-13 (expressing MLL-AF9) human leukemia cell lines(B) Titration curves from MTT cell viability assay after 7 days of treatment with M
BMCs; mean ± SD, n = 4.
(C) Titration curves from MTT assay performed for 7 days of treatment of human M
KOPN-8 (MLL-ENL), and SEM (MLL-AF4) and control AML cell lines without MLL
(D) Wright-Giemsa-stained cytospins for MLL-AF9 transformed BMCs after 10 d
(E) Quantification of CD11b expression in MLL-AF9 transformed BMCs treated for
(F) Wright-Giemsa-stained cytospins for MV4;11 and MOLM-13 after 7 days of t
(G) Apoptosis and cell death induced by MI-463 andMI-503 after 7 days of treatm
staining was detected by flow cytometry; mean ± SD, n = 2.
(H) qRT-PCR performed in MLL-AF9 BMCs after 6 days of treatment with MI-46
referenced to DMSO-treated cells; mean ± SD, n = 2.
(I) Long-term viability studies with different concentrations of MI-503 in MV4;11 c
subsequent 10 days of additional treatment. Viable cells were normalized to DM
(J) qRT-PCR performed in MV4;11 cells upon treatment with MI-503 or DMSO at t
of HOXA9 and MEIS1 was normalized to 18S rRNA and referenced to DMSO-tre
Data in (I) and (J) represent mean values for duplicates ± SD. See also Figure S2upon treatment with MI-389 and MI-503 (Figures 3D and 3E).
We observed markedly downregulated expression of homeobox
genes (HOXA9, HOXA10, HOXA7, PBX3, and MEIS1) and other
downstream targets of MLL fusion proteins (DLX2, MEF2C,
and FLT3) and upregulation of MNDA, a differentiation marker
of myeloid cells (Figures 3D and 3E), consistent with the gene
expression data from themicroarray studies inMV4;11 cells (Fig-
ures 3A and 3B). Overall, these results demonstrate that pharma-
cologic inhibition of the menin-MLL interaction reverses the
gene expression signature in MLL-rearranged leukemia cells,
providing an attractive strategy to reprogram these cells toward
differentiation.
Menin-MLL Inhibitors Block Hematologic Tumors In Vivo
and Reduce MLL Leukemia Tumor Burden
We next aimed to establish the therapeutic potential of menin-
MLL inhibitors in vivo using mouse models of MLL leukemia.
First, we characterized the PK properties of MI-503 and MI-
463 in mice. Both compounds achieved high levels in periph-
eral blood following a single intravenous or oral dose, while
also showing high oral bioavailability (45% for MI-463 and
75% for MI-503) (Figures 4A and S4A). We then assessed the
effect of MI-463 and MI-503 on in vivo tumor growth in a mouse
xenograft model using MV4;11 human MLL leukemia cells
implanted into BALB/c nude mice. Both MI-463 and MI-503
induced strong inhibition of tumor growth with once-daily intra-
peritoneal (i.p.) administration, although MI-503 showed more
pronounced effects (Figure 4B). Treatment with MI-503 resulted
in a more than 80% reduction in MV4;11 tumor volume and
complete tumor regression in two mice. Pronounced tumor
growth inhibition correlated well with the level of both com-
pounds in the tumor samples (Figure S4B). Importantly, pro-
longed treatment (38 days) with MI-503 induced no toxicity in
mice, as reflected by no alterations in body weight and no
morphologic changes in liver and kidney tissues (Figures S4C
and S4D). Furthermore, gene expression studies performed in
samples isolated from the MV4;11 tumors revealed significant
reduction in expression of MLL fusion protein target genes,
HOXA9 and MEIS1, upon treatment with MI-503 and MI-463
(Figure 4C). Taken together, the reduction in tumor growth
correlated with a decrease in expression of MLL-fusion target
genes in vivo, validating on-target activities of MI-463 and
MI-503.I-463 and MI-503 of MLL-AF9 and Hoxa9/Meis1 (HM-2) transformed murine
LL leukemia cell lines with MI-503: MV4;11 (MLL-AF4), MOLM-13 (MLL-AF9),
translocations: HL-60, NB4, and Jurkat; mean ± SD, n = 4.
ays of treatment with MI-503.
7 days with MI-463 andMI-503 detected by flow cytometry; mean ± SD, n = 2.
reatment with MI-503.
ent in the MLL-AF9 BMC. Quantification of Annexin V and Propidium Iodide (PI)
3 and MI-503. Expression of Hoxa9 and Meis1 was normalized to b-actin and
ells. Cells were treated for 10 days, followed by 10 days of no treatment with
SO control.
he end of each treatment or withdrawal phase (days 10, 20, and 30). Expression
ated cells.
.
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Figure 3. Effect of Menin-MLL Inhibitors on Gene Expression in MLL-Rearranged Human Leukemia Cells
(A and B) GSEA of genes downregulated upon treatment with MI-389 in MV4;11 cells compared with genes bound by MLL-AF4 in human SEM cells (Guenther
et al., 2008) (A) or MLL-AF9 targets (Bernt et al., 2011) (B).
(C) GSEA of genes upregulated by MI-389 treatment of MV4;11 cells compared with genes underexpressed in primitive hematopoietic progenitor cells (Jaatinen
et al., 2006). The heatmaps show genes comprising the leading edge of the GSEA plots. Red indicates high expression, blue indicates low expression. Triplicate
samples were used for global gene expression studies. NES, normalized enrichment score; FDR, false discovery rate.
(D) qRT-PCR performed in MV4;11 cells after 10 days of treatment with 0.6 mM of MI-503.
(E) qRT-PCR performed in MOLM-13 cells after 6 days of treatment with MI-389 (2 mM) or MI-503 (1 mM).
Expression of genes in (D) and (E) was normalized to 18S rRNA and referenced to DMSO-treated cells. Data in (D) and (E) represent mean values for duplicates ±
SD. See also Figure S3 and Table S4.We then assessed the effect of MI-503 and MI-463 in dissem-
inated human MLL-AF4 leukemia using a xenotransplantation
model. MV4;11 cells expressing luciferase were injected into
NSGS or NSG mice via the tail vein, and treatment was initiated
5 days later to allow efficient engraftment of leukemic cells. Leu-
kemia progression was monitored by bioluminescence imaging.
On the basis of the PK profiles, we selected a twice-daily treat-
ment regimen to sustain a therapeutic concentration of the com-
pounds in the blood. Ten consecutive days of treatment with
MI-503 resulted in a marked delay in the progression of MLL leu-
kemia in mice and significantly reduced leukemia tumor burden
(Figures 4D and S4E). Similarly, 20-day treatment of MV4;11
xenograft recipient mice with MI-463 also resulted in a substan-
tial delay in leukemia progression as manifested by a marked
decrease in the bioluminescence level measured over the course
of the experiment (Figures 4E and 4F). Reduced biolumines-
cence was associated with a significant decrease in the popula-
tion of leukemic cells in the peripheral blood, spleen, and bone
marrow samples harvested from mice treated with MI-463 (Fig-594 Cancer Cell 27, 589–602, April 13, 2015 ª2015 Elsevier Inc.ure 4G). Furthermore, we observed reduced expression of MLL
fusion target genes (HOXA9, MEIS1, and MEF2C) and an
increase in the expression level of ITGAM upon treatment of
mice with MI-463 (Figure 4H). Collectively, these findings
demonstrate that MI-503 and MI-463 have a potent anti-
leukemic effect in vivo when applied as single agents. Impor-
tantly, these data suggest that resistance did not emerge after
prolonged (20-day) treatment with MI-463.
Menin-MLL Inhibitors Substantially Improve Survival of
MLL Leukemic Mice
Wenext assessed the effects ofmenin-MLL inhibitors on survival
of MLL leukemia mice, using a bone marrow transplantation
model of murine MLL-AF9 leukemia (Figure S5A). Despite short
latency time in this aggressive leukemia model (15 days), we
initiated treatment 5 days after transplantation to test the effi-
cacy of menin-MLL inhibitors in the established disease model.
MI-463 at 50 mg/kg and MI-503 at 80 mg/kg were administered
twice daily by oral gavage for 10 consecutive days. The presence
Figure 4. Menin-MLL Inhibitors Block Hematological Tumors In Vivo, Increase Survival, and Reduce MLL Leukemia Tumor Burden
(A) PK studies in mice performed for MI-503 (top, mean ± SD, n = 2) andMI-463 (bottom, mean ± SD, n = 2) demonstrating blood concentration of the compounds
after oral (p.o.) dose of 30 or 100 mg/kg as well as intravenous (i.v.) administration at 15 mg/kg.
(B) In vivo inhibition of the tumor growth byMI-503 (top) andMI-463 (bottom) after subcutaneous injection of 0.53 107 MV4;11 cells into BALB/c nudemice, n = 6
per group. Mice were treated once daily with MI-503 (60 mg/kg) or MI-463 (35 mg/kg) via i.p. injection (p < 0.003 for each compound). Error bars represent SEM.
(C) Expression of HOXA9 andMIES1measured by qRT-PCR of RNA extracted from tumor samples harvested at the endpoint of treatment with MI-503 (day 38,
top) or MI-463 (day 28, bottom). HOXA9 andMEIS1 transcripts levels are normalized to the mean transcript level in tumors from the vehicle-treated groups; n = 4
per group. Boxes represent the first and third quartiles, the line represents the median, and the whiskers show the lowest and the highest values.
(D) Bioluminescent imaging of NSGS mice transplanted with MV4;11 human MLL leukemia cells expressing luciferase at the indicated days after initiation of
treatment with MI-503 (60 mg/kg, twice daily every 12 hr, i.p.) or vehicle, n = 9 mice per group.
(E) Quantification of bioluminescence imaging in NSGmice transplanted with luciferase-expressingMV4;11 cells at the indicated days after initiation of treatment
with MI-463 (45 mg/kg, twice daily, p.o.) or vehicle, n = 6 or 7 mice per group. Error bars represent SEM.
(F) Bioluminescence imaging of mice from (E) on the last day of treatment (day 20).
(legend continued on next page)
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of abundant blasts in the peripheral blood, bone marrow, and
spleen was used to validate terminal leukemia in mice (Fig-
ure S5B). Importantly, treatment with either compound strongly
delayed leukemia progression, as reflected by a substantial sur-
vival benefit inMLL-AF9 leukemiamicewhenMI-463 andMI-503
were applied as single agents (Figure 5A). The median survival of
MLL-AF9 leukemia mice was increased by 70% and 45%
upon treatmentwithMI-463 andMI-503, respectively (Figure 5A),
demonstrating their pronounced effects in blocking MLL leuke-
mia progression in vivo.
To further validate that treatment with menin-MLL inhibitors
delayed leukemia progression, we additionally tested the MI-
463 compound in the MLL-AF9 leukemia model using the
same treatment regimen as in the survival experiment (Figure 5A).
After 10 days of treatment, all animals were sacrificed, and
extensive analysis of leukemia progression was performed in
vehicle- and compound-treated cohorts, with samples collected
at the same time point. We observed notably reduced spleen
size and weight (Figures 5B and 5C) and substantially decreased
level of blasts in bone marrow samples upon treatment with MI-
463 versus vehicle control (Figures 5D and 5E). These effects
were accompanied by substantially reduced blast infiltration
of the liver and spleen upon treatment with MI-463 (Figures 5F
and S5C). The bone marrow samples isolated from mice treated
with MI-463 showed a subpopulation of cells with a differenti-
ated phenotype, as manifested by the appearance of cells with
a neutrophil-like morphology (Figure 5G). The white blood cell
(WBC) count was decreased in the peripheral blood of the
MLL-AF9 mice upon treatment with MI-463, while other blood
cells and blood parameters were not affected (Figures 5H and
S5D). MI-463 administration was well tolerated, and no signifi-
cant body weight loss was observed (Figure S5E). Furthermore,
treatment of mice with MI-463 resulted in a marked reduction in
the expression level of MLL-fusion downstream targets, Hoxa9,
Meis1, Mef2c, and Flt3, as well as a substantial increase in the
expression level of Itgam differentiation marker in the bone
marrow samples (Figure 5I). Taken together, these data demon-
strate that pharmacologic inhibition of the menin-MLL interac-
tion substantially delays progression of MLL leukemia in vivo
in murine models through on-target activity without causing
toxicity.
Menin-MLL Inhibitors Do Not Impair Normal
Hematopoiesis In Vivo
Given the role of MLL1 in normal hematopoiesis (Ernst et al.,
2002; McMahon et al., 2007), we assessed whether pharmaco-
logical inhibition of the menin-MLL interaction affects the normal
hematopoiesis in mice. C57BL/6 mice were treated with effica-
cious doses of MI-463 and MI-503 for 10 days using the same
treatment regimen as in survival experiments (Figure 5A). Impor-
tantly, no decrease in body weight, organ weight, or tissue
damage was observed upon treatment with either compound(G) Flow cytometry quantification of human CD45+ cells in blood, spleen, and bo
after last treatment (day 20) with MI-463 or vehicle. Error bars represent SEM, n
(H) Expression ofHOXA9,MIES1,MEF2C, and ITGAMmeasured by qRT-PCR of R
MI-463 or vehicle. Transcripts levels are normalized to GAPDH and referenced
independent samples per group). Error bars represent SEM.
See also Figure S4.
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bone marrow samples and found that bone marrow cellularity
was preserved upon treatment with MI-463 and MI-503 (Fig-
ure 6A). Flow cytometric analysis showed that BMC populations
highly enriched for hematopoietic stem cells were not decreased
upon treatment with menin-MLL inhibitors (LSK progenitors
defined as LinSca-1+c-Kit+ and long-term hematopoietic
stem cells defined as LSK CD48CD150+) (Figure 6B). In fact,
these populations were even slightly increased upon treatment.
Analysis of mature myeloid cells (CD11b+Gr-1+) showed no
impact in the inhibitor-treatedmice (Figure 6C). Phenotypic anal-
ysis of B cell populations showed a mild increase in pro-B cell
numbers and no effect on other B cells populations upon
treatment with MI-463 and MI-503 (Figures 6D and S6D). Gene
expression analysis performed in LSK progenitors showed no
reduction in the expression level of themenin and/orMLL depen-
dent genes, including Hoxa9 andMeis1, upon treatment of mice
with MI-463 or MI-503 (Figures 6E and S6E). This is consistent
with the modest effect on expression of these genes reported
in LSKs after genetic loss of Men1 encoding menin (Artinger
et al., 2013; Li et al., 2013; Maillard et al., 2009). These results
suggest that the MLL-rearranged cells are more sensitive to
the treatment with the menin-MLL inhibitors than normal LSKs,
supporting the existence of a therapeutic window for these
compounds.
We also assessed the effect of MI-503 on normal hematopoi-
esis after prolonged treatment of mice (38 days of continued
treatment with efficacious doses of MI-503) using the xenograft
MV4;11 model described above (Figure 4B). No significant ef-
fects on bone marrow cellularity, Linc-Kit+ progenitors, and
long-term hematopoietic stem cells were observed (Figures 6F
and 6G), with a slight increase in mature myeloid cells in bone
marrow (Figure 6F). Overall, these findings show that pharmaco-
logic inhibition of the menin-MLL interaction does not negatively
affect normal hematopoiesis, which rules out a potential ‘‘on-
target’’ toxicity of the menin-MLL inhibitors. Importantly, our re-
sults are in agreement with recent studies suggesting that menin
is not a requisite cofactor of MLL1 during normal hematopoiesis
(Li et al., 2013; Maillard and Hess, 2009).
Menin-MLL Inhibitors Selectively Kill MLL Leukemia
Primary Patient Samples
To evaluate therapeutic potential of menin-MLL inhibitors, we
studied the effects of MI-503 and MI-463 on primary samples
isolated from MLL leukemia patients as well as in several AML
patient samples without MLL translocation (Figures S7A and
S7B). Both compounds substantially reduced clonogenic effi-
ciency in all MLL leukemia patient samples, with more than
50% reduction in colony number at sub-micromolar or low-
micromolar concentrations (Figure 7A). Notably, the morphology
and size of colonies changed upon treatment with menin-MLL
inhibitors, resulting in significantly smaller and more diffusene marrow samples harvested from NSG mice transplanted with MV4;11 cells
= 5 or 6.
NA extracted from spleen samples harvested after last treatment (day 20) with
to the mean transcript level in vehicle treated group, which is set as 1 (n = 6
Figure 5. Treatment with Menin-MLL Inhibitor Blocks Progression of MLL Leukemia In Vivo
(A) Kaplan-Meier survival curves of vehicle and MI-503 or MI-463 treated C57BL/6 mice transplanted with 1 3 105 syngeneic MLL-AF9 leukemic cells isolated
fromprimary recipient mice (n = 9mice per group). Time of treatment is indicated on each graph. The p valueswere calculated using the log rank (Mantel-Cox) test
and are <0.0001 for each compound.
(B) Representative photographs of the spleen from control- and MI-463-treated (40 mg/kg, twice daily, p.o.) MLL-AF9 leukemia mice (n = 6 or 7 mice per group).
Treatment was initiated 5 days after transplantation and continued for 10 days. Samples from all mice were collected 1 day after treatment was stopped.
(C) Comparison of spleen weight for the MLL-AF9 leukemia mice treated with vehicle (n = 6) or MI-463 (n = 7), treatment as described in (B); mean ± SEM.
(D) Quantification of leukemic blasts in bone marrow of MLL-AF9 leukemia mice upon treatment with MI-463 or vehicle (n = 6 mice per group) by flow cytometry
analysis. GFP is detected as a surrogate forMLL-AF9 expressed from theMigR1 vector, reflectingMLL-AF9 expressing leukemic blasts. Boxes represent the first
and third quartiles, the line represents the median, and the whiskers show the lowest and the highest values.
(E) Representative histograms from flow cytometry analysis of the leukemic blasts in bone marrow samples of the MLL-AF9 mice treated with vehicle or MI-463.
SS, side scatter.
(F) Histological sections of liver parenchyma from control and MI-463 treated mice.
(legend continued on next page)
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colonies compared with DMSO-treated samples (Figure 7C). In
contrast, both compounds had little effect on colony formation
in control AML patient samples, except at the highest concentra-
tion (6 mM) in the AML-9571 sample (Figures 7B and 7C).
We also assessed the effect of MI-463 in an additional set of
AML patient samples and observed a marked decrease in cell
growth and blast population in MLL leukemia patient samples
but not in primary AML samples withoutMLL translocations (Fig-
ures 7D, 7E, S7C, and S7D). Furthermore, increased cell size
was observed after treatment withMI-463, specifically in primary
MLL leukemia cells but not in other AML samples (Figure 7E),
suggesting differentiation of these cells, although this effect
needs further investigation. No effect on growth and blast
population in the primary MLL patient samples was detected
for MI-372 negative control compound (Figures S7C–S7E).
Taken together, these data provide compelling evidence sup-
porting the therapeutic potential of menin-MLL inhibitors in
MLL leukemias.
DISCUSSION
Acute leukemias with MLL rearrangements represent an unmet
medical need, as therapeutic agents have not been developed
for clinical use in MLL leukemia patients. Menin plays a critical
role as an oncogenic co-factor of MLL fusion proteins in leuke-
mia (Yokoyama et al., 2005). On the basis of genetic data, inhibi-
tion of the menin-MLL interaction was proposed as a potential
therapeutic approach (Li et al., 2013; Yokoyama et al., 2005),
but this strategy has not been validated with pharmacologic
agents. Here, we demonstrate that pharmacologic inhibition of
the menin-MLL interaction with small molecules blocks progres-
sion of MLL leukemia in vivo without impairing normal hemato-
poiesis. These effects were achieved with the small-molecule
inhibitors MI-463 and MI-503, which directly bind to menin with
low-nanomolar binding affinities and effectively block the me-
nin-MLL interaction. Both compounds have appropriate PK pro-
files and high oral bioavailability, and their in vivo administration
results in a substantial extension of survival in a mouse model of
MLL leukemia through on-target mechanism of action. Impor-
tantly, these compounds do not impair normal hematopoiesis
in mice, providing evidence that a sufficient therapeutic window
can be achieved. Overall, this study supports clinical applica-
tions of menin-MLL inhibitors as targeted therapeutics against
MLL-rearranged leukemias.
On the basis of our studies, MI-463 and MI-503 are two lead
compounds with comparable efficacy and druglike properties.
MI-503 has better oral bioavailability and can be tolerated at
higher doses in mice, but at this point, we cannot distinguish
which compound might represent a better candidate for further
development as targeted therapy for the treatment of patients(G) Wright-Giemsa-stained cytospins for bone marrow samples isolated from ML
with neutrophil-like morphology in MI-463 treated mice are indicated by black ar
(H) Treatment with MI-463 reduces WBC level in the peripheral blood; mean ± S
(I) Expression of Hoxa9, Meis1, Mef2c, Flt3, and Itgam measured by qRT-PCR o
treatment (treatment was continued for 10 days) with MI-463 or vehicle. Transcrip
vehicle treated group, which is set as 1 (n = 4 replicates per group). Boxes represe
show the lowest and the highest values.
See also Figure S5.
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ical formulation, PK studies, and long-term toxicity in other
species, including rats and dogs, are required to address this
question. In case any potential undesired side effects emerge,
additional substitutions on the indole ring of MI-463 or MI-503
could be explored to modulate these properties.
In this study, we provide an example of targeted drug discov-
ery whereby the oncogenic effects of genetic alterations can be
reversed by effective blocking of a protein-protein interaction
critical for oncogenesis. This approach represents an attractive
strategy to develop therapies, as protein-protein interactions
typically show a high level of evolutionary conservation, and
functional mutations leading to drug resistance are far less likely
to occur than in enzymes. These considerations, together with
the results of our studies, validate that in vivo pharmacological
inhibition of the menin-MLL fusion protein interaction offers a
promising therapeutic opportunity for acute leukemias with
MLL rearrangements. Recent reports emphasize oncogenic
role of menin in other cancers, including hepatocellular carci-
nomas (Xu et al., 2013), raising a possibility that pharmacologic
inhibition of this protein-protein interaction might have broader
therapeutic applications in oncology, for both hematologic
malignancies and solid tumors. The two compounds we report
here may represent clinical lead candidates or provide an
advanced molecular scaffold for further optimization into clinical
lead compounds.
EXPERIMENTAL PROCEDURES
Chemistry
Chemical synthesis and chemical characterization of compounds are provided
in Supplemental Experimental Procedures.
Biochemical, Biophysical, andStructural Characterization ofMenin-
MLL Inhibitors
Inhibition of the menin-MLL interaction by small molecules was assessed by
fluorescence polarization assay using the protocol described previously
(Grembecka et al., 2010, 2012). Binding affinity of compounds (MI-136, MI-
389, MI-463, and MI-503) to menin was assessed using isothermal titration
calorimetry (ITC) experiments performed at 25C with compounds (50–
100 mM) injected into menin (5–10 mM) in 10 ml aliquots. For co-crystallization
experiments, 2.5 mg/ml menin was incubated with small-molecule inhibitors
(MI-136 or MI-503) in a 1:3 molar ratio. Crystals were obtained using the sitting
drop technique at 10C by applying the procedure described previously (Shi
et al., 2012). More details can be obtained in Supplemental Experimental
Procedures.
Viability Assays, Cell Differentiation, and Gene Expression Studies
For viability assays, leukemia cells were plated at relevant concentrations and
treated with compounds or 0.25%DMSO and cultured at 37C for 7 days. Me-
dium was changed at day 4, viable cell numbers were restored to the original
concentration, and compounds were re-supplied. The MTT cell proliferation
assay kit (Roche) was then used, and plates were read for absorbance atL-AF9 mice treated with MI-463 and vehicle (treatment described in B). BMCs
rows.
EM, n = 6.
f RNA extracted from bone marrow samples harvested the next day after last
ts levels are normalized to b-actin and referenced to the mean transcript level in
nt the first and third quartiles, the line represents the median, and the whiskers
Figure 6. Pharmacologic Inhibition of the Menin-MLL Interaction Does Not Impair Normal Hematopoiesis in Mice
(A) Analysis of bone marrow (BM) cellularity after 10 days of treatment of normal C57BL/6 mice with MI-463 (40 mg/kg), MI-503 (70 mg/kg), or vehicle control
(twice daily via oral gavage; n = 8 or 9/group, mean ± SD).
(B) Representative histograms from flow cytometry analysis of hematopoietic stem and progenitor cells: LSK (LinSca-1+c-Kit+) and long-term repopulating cells
(LT-HSC, defined as LinSca-1+c-Kit+CD48CD150+) (left). (Right) Quantification of LSK and LT-HSC cell frequency by flow cytometry (n = 8 or 9/group, mean ±
SD), *p < 0.05, ***p < 0.001 (treatment described in A).
(C) Representative histograms (left) and quantification (right) from flow cytometry analysis of mature myeloid cells in BM samples isolated frommice treated with
vehicle, MI-463, or MI-503 (n = 8 or 9/group, mean ± SD); treatment described in (A).
(D) Representative histograms (left) and quantification (right) from flow cytometry analysis of BMpro-B cell populations (B220+CD43hisIgMnegCD19+AA4.1+) (n = 8
or 9/group, mean ± SD), *p < 0.05.
(E) Expression ofHoxa9measured by qRT-PCR of RNA extracted from LSK cells harvested after 10 days of treatment withMI-463,MI-503, or vehicle. Transcripts
levels are normalized to Hprt1 and referenced to the mean transcript level in the vehicle-treated group, which is set as 1 (n = 5 or 6 per group), mean ± SD.
(legend continued on next page)
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570 nm using a PHERAstar BMG microplate reader. Effect of menin-MLL in-
hibitors on expression level was assessed by qRT-PCR after 6 days of incuba-
tion of compounds with cells, with medium changed and compound re-supply
at day 3. For cell differentiation studies, leukemia cells were treated with me-
nin-MLL inhibitors for 7 days, then harvested, washed, and incubated with Pa-
cific Blue rat anti-mouse CD11b antibody (BD BioLegend, catalog no. 101224)
before being analyzed by flow cytometry. More details can be obtained in Sup-
plemental Experimental Procedures.
Efficacy Studies in Mice
All animal experiments were approved by the University of Michigan Commit-
tee on Use and Care of Animals and Unit for Laboratory Animal Medicine. For
efficacy studies in MV4;11 subcutaneous xenograft mice model, 53 106 cells
were injected into the 4 to 6 week old female BALB/c nude mice. Treatment
was started when the tumor size reached 100 mm3. Vehicle (25% DMSO,
25% PEG400, 50% PBS) or compounds (MI-463 or MI-503) were adminis-
trated once daily at designated doses using i.p. injections. For mice efficacy
studies in bioimaging MV4;11 xenograft model, 6 to 8 week old female
NSGS or NSGmice were intravenously injected with 13 107 or 0.53 107 lucif-
erase-expressing MV4;11 cells. At day 5, treatment with compound of vehicle
was initiated and continued for 10 to 20 consecutive days. To generate the
MLL-AF9 leukemic mice, C57BL/6 female mice were transplanted with 1 3
105 spleen or BMCs isolated from the primary recipient mice. Five days
post-transplantation treatment with MI-463, MI-503 or vehicle was initiated
and continued for 10 days. Mice were sacrificed upon signs of disease. Leuke-
mia was confirmed by flow cytometric analysis of GFP+ cells as a surrogate for
MLL-AF9 expression. More details can be obtained in Supplemental Experi-
mental Procedures.
Analysis of Normal Hematopoiesis in Mice
Normal hematopoiesis was studied in C57BL/6mice after 10 days of treatment
with MI-463, MI-503, or vehicle control and in the BALB/c nude mice after
38 days of treatment withMI-503. See Supplemental Experimental Procedures
for more details.
Primary Patient Samples
Patient-derived AML samples were collected in accordance with the guide-
lines and approval of institutional review boards at University of Pennsylvania
Hospital, Weill Cornell Medical College, New York Presbyterian Hospital, and
the University of Michigan Hospital, and informed consent from each patient.
Peripheral blood samples were collected and processed to isolate mononu-
clear cells using density gradient centrifugation and red blood cell lysis. Cells
were frozen in 10% DMSO until used in experiments.
Clonogenic Assay in Methylcellulose with Primary Patient Samples
Primary patient samples were grown in RPMI-1640 media (Lifetechnologies),
supplemented with 10% FBS and 1% penicillin/streptomycin, in the presence
of 10 ng/ml human IL-3, 10 ng/mL IL-6, and 50 ng/m LSCF (PeproTech).
Twenty-four hours later, cells were plated in duplicate on methylcellulose
medium supplemented with human cytokines (Methocult H4435; StemCell
Technologies) with cell density of 7.5 to 15 3 104 cells. Compounds or
DMSO were added to the methylcellulose and incubated at 37C, 5% CO2,
for 14 days, at which time colonies were stained with iodonitrotetrazolium
chloride and counted.
Cell Viability Assay in Primary Patient Samples
Primary AML samples were treated with the compounds or vehicle (0.25%
DMSO) for 7 days. Cells were collected and stained with mouse anti-
human CD45-APC-H7 (BD Bioscience), CD34-APC, and CD38-PE-Cy7
(eBiosciences) prior to Annexin V (BD Bioscience) and 7-AAD (Life Technolo-
gies) staining. Cells were then analyzed using an LSR II flow cytometer (BD(F) Analysis of BM cellularity and mature myeloid cells after 38 days of treatment
xenograft mice (BALB/c nude); mean ± SD, n = 5 or 6 per group.
(G) Analysis of hematopoietic progenitor cells after 38 days of treatment with M
performed in the subcutaneous MV4;11 xenograft mice (BALB/c nude), *p < 0.05
See also Figure S6.
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was performed using FlowJo 9.3.2 software for Mac OS X (TreeStar). Annexin
V and 7-AAD double negative cells were scored as viable, and the viability was
represented as the percentage relative to DMSO-treated cells.
Statistical Analysis
Student’s t test (unpaired, two-tailed) was used to calculate significance level
between treatment groups in all experiments besides survival curves, in which
the log rank (Mantel-Cox) test was applied to calculate p values. A p value <
0.05 was considered significant. Graph generation and statistical analysis
were performed using GraphPad Prism version 6.02 software (GraphPad
Software).
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Information Gene Expression Omnibus database under accession number
GSE60673. Crystallographic data were deposited in the Protein Data Bank
under accession numbers 4X5Y (menin-MI-503 complex) and 4X5Z (menin-
MI-136 complex).
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